Aurigene, Curis deal

Curis exercised its options to license two preclinical small molecule programs from Aurigene to treat cancer and cytokine-driven inflammatory and autoimmune diseases. The programs include CA-170, an oral antagonist of PD-L1 and V-region immunoglobulin-containing suppressor of T cell activation (VISTA), and oral inhibitors of IL-1 receptor-associated kinase 4 ( IRAK4).

Curis will pay Aurigene an option fee of $6 million in exchange for exclusive, worldwide licenses to both programs, except in India and Russia, where Aurigene will retain rights. Aurigene is eligible for up to $52.5 million in regulatory and sales milestones per program, including up to $10 million in an option exercise fee, a preclinical milestone and development milestones. Aurigene is also eligible for high single-digit royalties up to 10%. Curis gained the options under a January deal. ...